Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign

Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial

(2022) Etienne Karita et al.   Trials

Febrile seizures in an urban Tanzanian population: lessons learned from a community‐based random cluster survey

(2021) Dominik Stelzle et al.   TROPICAL MEDICINE & INTERNATIONAL HEALTH

Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda

(2020) Jonathan Kitonsa et al.   Global Health Action

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

(2020) Andrew J Pollard et al.   LANCET INFECTIOUS DISEASES

Ebola virus disease

(2019) Denis Malvy et al.   LANCET

Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Uganda and Tanzania

(2019) Zacchaeus Anywaine et al.   JOURNAL OF INFECTIOUS DISEASES

Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Nairobi, Kenya

(2019) Gaudensia Mutua et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines

(2016) Iain D. Milligan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Common variants associated with general and MMR vaccine–related febrile seizures

(2014) Bjarke Feenstra et al.   NATURE GENETICS

Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children

(2013) Hung Fu Tseng et al.   VACCINE

Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination

(2013) Tania Schink et al.   VACCINE

Febrile seizures after 2010–2011 influenza vaccine in young children, United States: A vaccine safety signal from the vaccine adverse event reporting system

(2012) Z. Leroy et al.   VACCINE

Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010

(2012) Claude-Roger Ouandaogo et al.   VACCINE